People: Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

1.96USD
21 May 2013
Price Change (% chg)

$-0.02 (-1.01%)
Prev Close
$2.01
Open
$1.98
Day's High
$2.02
Day's Low
$1.95
Volume
710,234
Avg. Vol
1,430,642
52-wk High
$2.77
52-wk Low
$1.14

Search Stocks

Summary

Name Age Since Current Position

James Young

 59 2011 Independent Chairman of the Board

Stanley Erck

 64 2011 President, Chief Executive Officer, Director

Gregory Glenn

 59 2011 Senior Vice President, Chief Medical Officer

Timothy Hahn

 49 2011 Senior Vice President - Manufacturing and Process Development

Russell Wilson

 53 2011 Senior Vice President - Business Development

Rajiv Modi

 52 2009 Director

Richard Douglas

 59 2010 Independent Director

Gary Evans

 55 2011 Independent Director

John Marsh

 85 1997 Independent Director

Michael McManus

 69 1998 Independent Director
» Insider Trading

Biographies

Name Description

James Young

 Dr. James F. Young is an Independent Chairman of the Board of Novavax, Inc. since April 2011. He was Former President, Research and Development, MedImmune, Inc. Dr. Young has been Chairman of the Board since April 2011 and a Director of Novavax since April 2010. He has 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. From December 2000 until June 2008, Dr. Young held the position of President, Research and Development, at MedImmune. Dr. Young joined MedImmune in 1989 as Vice President, Research and Development. In 1995, he was promoted to Senior Vice President and in 1999 he was promoted to Executive Vice President, Research and Development.

Stanley Erck

 Mr. Stanley C. Erck is President, Chief Executive Officer, Director of Novavax, Inc., since April 19, 2011, formerly Executive Chairman since February 2010, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now known as Genzyme and Baxter International. Mr. Erck also serves on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and MdBio Foundation.

Gregory Glenn

 Dr. Gregory M. Glenn M.D. is Senior Vice President, Chief Medical Officer of Novavax, Inc., since January 2011. He served as Senior Vice President and Chief Scientific Officer from July 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research.

Timothy Hahn

 Dr. Timothy J. Hahn Ph.D. is Senior Vice President - Manufacturing and Process Development of Novavax Inc., since June 28, 2011. Prior to joining the Company, Dr. Hahn was Vice President of Antibody Manufacturing and later Vice President of Vaccine Manufacturing at MedImmune, LLC, with responsibilities for both U.S. and non-U.S. manufacturing sites. Dr. Hahn spent more than 15 years in vaccine manufacturing with Merck & Co.

Russell Wilson

 Mr. Russell P. Wilson is Senior Vice President - Business Development of Novavax, Inc., since November 2011. Mr. Wilson was most recently the Chief Financial Officer at Supernus Pharmaceuticals beginning in 2009. He was previously Senior Vice President, Chief Financial Officer and General Counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG. He was the Acting General Counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000.

Rajiv Modi

 Dr. Rajiv I. Modi is Director of Novavax, Inc., since April 1, 2009. He is Managing Director of Cadila Pharmaceuticals, Ltd. (“Cadila”), a company organized in India, since 1995 and Director of other Cadila Group Companies. Dr. Modi was elected to the Board based upon his relationship with the Company’s shareholder at the time. As of April 16, 2012, Satellite Overseas (Holdings) Limited, a subsidiary of Cadila, holds approximately 10.2% of the Company’s Common Stock and, for so long as it holds at least 5% of the Common Stock, the Board will nominate for election as a director one representative of Cadila.

Richard Douglas

 Dr. Richard H. Douglas is an Independent Director of Novavax, Inc., since 2010. He is Former Senior Vice President Corporate Development and a Corporate Officer of Genzyme Corporation. From 1989 to 2011 he led Genzyme’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. He received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan. He serves on the University of Michigan Technology Transfer National Advisory Board.

Gary Evans

 Mr. Gary C. Evans is an Independent Director of Novavax, Inc. He is Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation, a NYSE Amex listed oil and gas company since May 2009 and Chairman, President, Chief Executive Officer and Founder of GreenHunter Energy, Inc., a NYSE Amex listed alternative energy company, since 2007. Former Lead Independent Director of Novavax from March 2007 until April 2011 and Chairman of the Board of Directors of Novavax from April 2005 until March 2007. Mr. Evans was Chairman, President and Chief Executive Officer of Magnum Hunter Resources, Inc., a NYSE listed oil and gas exploration and production company, from 1995 to 2005 and Chairman and Chief Executive Officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Mr. Evans is an Individual Trustee of TEL Offshore Trust, a publicly listed oil and gas trust and serves on the Board of the Maguire Energy Institute at Southern Methodist University.

John Marsh

 Mr. John O. Marsh is an Independent Director of Novavax, Inc., since 1991. He is Distinguished Adjunct Professor of Law at George Mason University. Mr. Marsh was the Co-Chair of the Independent Review Group for Walter Reed Hospital and Bethesda Navy Medical Center. Mr. Marsh was a Visiting Professor of Ethics at Virginia Military Institute in 1998. He served as Interim Chief Executive Officer of Novavax from July 1996 to March 1997 and as Chairman of the Company’s Board of Directors from July 1996 to February 1997. He was Secretary of the Army from 1981 to 1989, a Counselor with Cabinet rank to the President of the United States from 1974 to 1977, Assistant for National Security Affairs to Vice President of the United States in 1974, and Assistant Secretary of Defense from 1973 to 1974. Mr. Marsh was a U.S. Representative in Congress from 1963 to 1971. He has been awarded the Department of Defense Distinguished Public Service Award on six occasions and was awarded the Presidential Citizens Medal from President Ronald Reagan. Mr. Marsh served on the executive committee of the Institute for Defense Analyses (IDA), a federal research institute, and continues to hold a consulting role with IDA.

Michael McManus

 Mr. Michael A. McManus is an Independent Director of Novavax, Inc., since 1998. He is President and Chief Executive Officer of Novavax since April 2011. Former Executive Chairman and Director of Novavax from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. He previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now known as Genzyme, and Baxter International. Mr. Erck serves on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and The MdBio Foundation.

Basic Compensation

Name Fiscal Year Total

James Young

 --

Stanley Erck

 1,416,270

Gregory Glenn

 543,078

Timothy Hahn

 338,697

Russell Wilson

 389,339

Rajiv Modi

 --

Richard Douglas

 --

Gary Evans

 --

John Marsh

 --

Michael McManus

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

James Young

 0 0

Stanley Erck

 0 0

Gregory Glenn

 0 0

Timothy Hahn

 0 0

Russell Wilson

 0 0

Rajiv Modi

 0 0

Richard Douglas

 0 0

Gary Evans

 0 0

John Marsh

 0 0

Michael McManus

 0 0

Insider Trading

Name Shares Traded Price

EVANS GARY C

 39,000 $2.46

EVANS GARY C

 40,000 $2.44

YOUNG JAMES F

 100,000 $2.03

HAHN TIMOTHY JON

 30,000 $1.33

GLENN GREGORY M

 25,000 $1.35

DOUGLAS RICHARD H

 50,000 $1.21

GLENN GREGORY M

 2,000 $1.50

YOUNG JAMES F

 200,000 $1.46

GLENN GREGORY M

 2,000 $1.26

EVANS GARY C

 476,576 $1.22

EVANS GARY C

 214,800 $1.25

ERCK STANLEY C

 13,000 $1.26

ERCK STANLEY C

 16,552 $1.24

TRIZZINO JOHN J

 10,000 $1.18

DRISCOLL FREDERICK W

 20,000 $1.18

TRIZZINO JOHN J

 10,000 $1.20

DOUGLAS RICHARD H

 50,000 $1.20

ERCK STANLEY C

 33,448 $1.24

DOUGLAS RICHARD H

 50,000 $2.04
» Full list on Insider Trading
Search Stocks